In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis acquires GSK’s cancer drug assets for $14.5bn up front

Executive Summary

Essentially ending its quest to be a leading oncology company, GlaxoSmithKline PLC divested to Novartis AG several cancer assets for $14.5bn up front, plus a $1.5bn development milestone dependent upon the results (specifically the achievement of a survival endpoint) in COMBI-d, a Phase III trial comparing the combination of dabrafenib (the BRAF inhibitor Tafinlar) and trametinib (the MEK inhibitor Mekinist) with dabrafenib alone in patients with stage IIIC or metastatic (stage IV) BRAF V600E/K mutation-positive cutaneous melanoma.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies